Literature DB >> 33975248

NLRP3 induces the autocrine secretion of IL-1β to promote epithelial-mesenchymal transition and metastasis in breast cancer.

Yuhao Wang1, Hongnan Zhang2, Yongjie Xu2, Tao Peng2, Xiaojing Meng3, Fei Zou4.   

Abstract

Tumor metastasis is a leading cause of mortality in patients with breast cancer (BC). As a predominant component of inflammasome, Nod-like receptor protein 3 (NLRP3) was found to be required for tumor progression, while the role of NLRP3 in BC metastasis remains largely undefined. In current study, we found that invasive BC had aberrant upregulation of NLRP3 expression, especially in the claudin-low subtype. And higher expression of NLRP3 predicted poor survival of BC patients. Further investigation suggested that NLRP3 promotes the migration and invasion, as well as the metastasis of BC cells. Moreover, we revealed that NLRP3 induces the autocrine secretion of IL-1β to promote epithelial-mesenchymal transition via a Caspase-1-dependent manner. Hence, this study suggested that upregulation of NLRP3 in BC induces the autocrine secretion of IL-1β and promotes EMT and metastasis of BC cells.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; EMT; IL-1β; Metastasis; NLRP3

Year:  2021        PMID: 33975248     DOI: 10.1016/j.bbrc.2021.04.122

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Downstream Signaling of Inflammasome Pathway Affects Patients' Outcome in the Context of Distinct Molecular Breast Cancer Subtypes.

Authors:  Concetta Saponaro; Annarita Fanizzi; Margherita Sonnessa; Paolo Mondelli; Daniele Vergara; Donato Loisi; Raffaella Massafra; Agnese Latorre; Francesco A Zito; Laura Schirosi
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

Review 2.  Overcoming Immunotherapy Resistance by Targeting the Tumor-Intrinsic NLRP3-HSP70 Signaling Axis.

Authors:  Balamayooran Theivanthiran; Tarek Haykal; Linda Cao; Alisha Holtzhausen; Michael Plebanek; Nicholas C DeVito; Brent A Hanks
Journal:  Cancers (Basel)       Date:  2021-09-23       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.